"Killer acquisitions" is to acquire innovative targets solely to discontinue the target’s innovation projects and preempt future competition.
Is the takeover of Resapp Health Ltd pegged for a killer acquisition?
We know that:
- ResappDx technology works, that is, CE Marked in Europe and TGA approved in Australia.
- There is potential for this technology to stop the misuse/overuse of antibiotics caused by misdiagnoses.
- Pfizer is one of the forerunners in the Antibiotics Market, which is projected to grow from $38.08 billion in 2021 to $45.30 billion in 2028.
- Researchers estimate that 7% of the acquisitions in the pharmaceutical industry are "killer acquisitions".
In addition, the overuse of antibiotics not only affects: people's health outcomes; but other systems as well.
Furthermore, the database of pre-covid cough sounds RAP has recorded, is a resource that can never be duplicated/reproduced.
- Forums
- ASX - By Stock
- RAP
- Is this a "Killer acquisition"?
Is this a "Killer acquisition"?
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online